- Home
- ABAT vs CRDL Comparison
ABAT vs CRDL Comparison
Compare ABAT & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABAT
- CRDL
- Stock Information
- Founded
- ABAT 2011
- CRDL 2017
- Country
- ABAT United States
- CRDL Canada
- Employees
- ABAT N/A
- CRDL N/A
- Industry
- ABAT Metal Mining
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABAT Basic Materials
- CRDL Health Care
- Exchange
- ABAT Nasdaq
- CRDL Nasdaq
- Market Cap
- ABAT 87.2M
- CRDL 80.1M
- IPO Year
- ABAT N/A
- CRDL N/A
- Fundamental
- Price
- ABAT $1.40
- CRDL $1.14
- Analyst Decision
- ABAT
- CRDL Strong Buy
- Analyst Count
- ABAT 0
- CRDL 3
- Target Price
- ABAT N/A
- CRDL $9.00
- AVG Volume (30 Days)
- ABAT 2.0M
- CRDL 151.6K
- Earning Date
- ABAT 05-19-2025
- CRDL 05-20-2025
- Dividend Yield
- ABAT N/A
- CRDL N/A
- EPS Growth
- ABAT N/A
- CRDL N/A
- EPS
- ABAT N/A
- CRDL N/A
- Revenue
- ABAT $877,900.00
- CRDL N/A
- Revenue This Year
- ABAT $31,748.62
- CRDL N/A
- Revenue Next Year
- ABAT N/A
- CRDL N/A
- P/E Ratio
- ABAT N/A
- CRDL N/A
- Revenue Growth
- ABAT N/A
- CRDL N/A
- 52 Week Low
- ABAT $0.73
- CRDL $0.77
- 52 Week High
- ABAT $4.11
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- ABAT 57.02
- CRDL 57.30
- Support Level
- ABAT $1.30
- CRDL $1.02
- Resistance Level
- ABAT $1.46
- CRDL $1.16
- Average True Range (ATR)
- ABAT 0.16
- CRDL 0.07
- MACD
- ABAT 0.01
- CRDL 0.01
- Stochastic Oscillator
- ABAT 47.14
- CRDL 82.38
About ABAT American Battery Technology Company
American Battery Technology Co is engaged in lithium-ion battery recycling, battery metals and material extraction, and resource production. It is a battery metals company producing low-cost battery metals with a commitment to closed-loop, clean energy technologies.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.